Omeros (NASDAQ:OMER)

CAPS Rating: 3 out of 5

Results 1 - 11 of 11

Recs

0
Member Avatar mplaut100 (< 20) Submitted: 4/26/2015 3:35:25 PM : Outperform Start Price: $24.47 OMER Score: -30.35

They have approved drugs and a good pipeline

Recs

0
Member Avatar Bobmoll36 (56.24) Submitted: 11/17/2014 1:38:23 PM : Outperform Start Price: $19.69 OMER Score: -17.85

in at 13. Rising well. good drug history

Recs

0
Member Avatar fdgaley (< 20) Submitted: 8/12/2014 5:13:29 PM : Outperform Start Price: $12.79 OMER Score: +23.98

Great Pipeline.

Recs

0
Member Avatar griderX (96.95) Submitted: 6/3/2014 10:12:34 AM : Outperform Start Price: $11.43 OMER Score: +36.21

Speculative Buy List

Recs

3
Member Avatar zzlangerhans (99.72) Submitted: 4/8/2014 12:34:14 AM : Outperform Start Price: $11.00 OMER Score: +36.88

Perhaps the secret PDUFA date for Omidria is keeping Omeros off run-up traders' catalyst calendars. The stock has been decidedly weak ahead of the FDA approval decision, which I project will occur in early June. Meanwhile, Omeros is attempting to escape from their grimy repurposer past with sexier new chemical entities OMS721 and OMS824. With a powerful catalyst approaching and a newly strengthened pipeline, Omeros could be a force to reckon with if the biopharma sector snaps out of its recent funk.

Recs

0
Member Avatar kcprojects (< 20) Submitted: 12/19/2013 6:41:16 PM : Outperform Start Price: $10.16 OMER Score: +46.99

FDA approval

Recs

0
Member Avatar pcguy (< 20) Submitted: 11/23/2013 2:42:56 AM : Outperform Start Price: $7.20 OMER Score: +113.64

FDA approval.

Recs

0
Member Avatar stover87 (< 20) Submitted: 2/4/2013 10:13:54 AM : Outperform Start Price: $5.61 OMER Score: +154.74

Q! 2013 NDA filing and mid 2013 filing in europe, looking very postive and phase 3 results exceeded expectations.

Recs

0
Member Avatar fox2man2 (< 20) Submitted: 10/6/2012 12:38:50 AM : Outperform Start Price: $10.29 OMER Score: +17.39

I believe OMER will outperform the S&P 500 by a considerable amount. I encourage Fools to go to its website and read about recent developments in its propieteray medical programs. That is a 15 minute task and well worth one's time. OMER has no income at this time, but expects approval of two drugs in 2013, one for arthroscopic knee surgery and a second for eye surgery. Daily trading volume has been small, however, and this should be considered by prospective investors.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 4/1/2011 11:03:52 AM : Underperform Start Price: $5.17 OMER Score: -162.41

this a warning for all beginners! why? so you can put the money in my stocks and so drive my winnings

Recs

0
Member Avatar cwstrand (< 20) Submitted: 10/21/2009 12:16:46 AM : Outperform Start Price: $6.85 OMER Score: +49.82

The patents this company holds are incredible. The breakthrough in patient treatment for pain post-surgery (in clinical trials) is outstanding for arthro, eye, uro, etc. are oustanding. Once any of the trials, in various phases now, hits, this will blow sky high.

Results 1 - 11 of 11

Featured Broker Partners


Advertisement